Business Description
TalkMed Group Ltd
ISIN : SG2G61000003
Description
TalkMed Group Ltd operates as an investment holding company. It is a provider of medical oncology, stem cell transplants and palliative care services, serving patients in Singapore and the region. Outside Singapore, the Group operates in Vietnam, Hong Kong and the People's Republic of China. The activities of the company are the provision of medical oncology services and palliative care healthcare services in Singapore. It is organized into two reportable operating segments, Oncology Services and Cellular and gene therapy-related products and services. The company has operational footprints across Singapore, China and Hong Kong, Australia, Vietnam and others of which Singapore contributes the vast majority of total revenue. It generates maximum revenue from the Oncology services segment.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.46 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | 0.23 | |||||
| Interest Coverage | 93.44 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 14.66 | |||||
| Beneish M-Score | -3.09 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.3 | |||||
| 3-Year EBITDA Growth Rate | 12.1 | |||||
| 3-Year EPS without NRI Growth Rate | 9.6 | |||||
| 3-Year FCF Growth Rate | 12.1 | |||||
| 3-Year Book Growth Rate | 2.6 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.02 | |||||
| 9-Day RSI | 51.28 | |||||
| 14-Day RSI | 51.03 | |||||
| 3-1 Month Momentum % | 9.76 | |||||
| 6-1 Month Momentum % | 16.88 | |||||
| 12-1 Month Momentum % | 15.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.85 | |||||
| Quick Ratio | 3.8 | |||||
| Cash Ratio | 3.56 | |||||
| Days Sales Outstanding | 39.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.89 | |||||
| Dividend Payout Ratio | 1.05 | |||||
| 3-Year Dividend Growth Rate | 8.1 | |||||
| Forward Dividend Yield % | 4.89 | |||||
| 5-Year Yield-on-Cost % | 5.51 | |||||
| 3-Year Average Share Buyback Ratio | -0.2 | |||||
| Shareholder Yield % | 4.64 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 41.45 | |||||
| Net Margin % | 35.02 | |||||
| FCF Margin % | 42.6 | |||||
| ROE % | 32.42 | |||||
| ROA % | 25.54 | |||||
| ROIC % | 101.83 | |||||
| 3-Year ROIIC % | 108.24 | |||||
| ROC (Joel Greenblatt) % | 343.62 | |||||
| ROCE % | 39.19 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21.43 | |||||
| PE Ratio without NRI | 21.43 | |||||
| Shiller PE Ratio | 15.59 | |||||
| Price-to-Owner-Earnings | 15.52 | |||||
| PEG Ratio | 13.39 | |||||
| PS Ratio | 7.5 | |||||
| PB Ratio | 7.14 | |||||
| Price-to-Tangible-Book | 7.5 | |||||
| Price-to-Free-Cash-Flow | 17.31 | |||||
| Price-to-Operating-Cash-Flow | 17.31 | |||||
| EV-to-EBIT | 15.85 | |||||
| EV-to-EBITDA | 14.6 | |||||
| EV-to-Revenue | 6.57 | |||||
| EV-to-FCF | 15.43 | |||||
| Price-to-GF-Value | 0.76 | |||||
| Price-to-Projected-FCF | 1.67 | |||||
| Price-to-Median-PS-Value | 0.78 | |||||
| Price-to-Graham-Number | 2.65 | |||||
| Price-to-Net-Current-Asset-Value | 9 | |||||
| Price-to-Net-Cash | 9 | |||||
| Earnings Yield (Greenblatt) % | 6.31 | |||||
| FCF Yield % | 5.64 | |||||
| Forward Rate of Return (Yacktman) % | 6.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TalkMed Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil S$) | 79.116 | ||
| EPS (TTM) (S$) | 0.021 | ||
| Beta | 0.13 | ||
| 3-Year Sharpe Ratio | 0.06 | ||
| 3-Year Sortino Ratio | 0.1 | ||
| Volatility % | 22.01 | ||
| 14-Day RSI | 51.03 | ||
| 14-Day ATR (S$) | 0.003788 | ||
| 20-Day SMA (S$) | 0.449 | ||
| 12-1 Month Momentum % | 15.38 | ||
| 52-Week Range (S$) | 0.355 - 0.5 | ||
| Shares Outstanding (Mil) | 1,327.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
TalkMed Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
TalkMed Group Ltd Stock Events
| Event | Date | Price (S$) | ||
|---|---|---|---|---|
| No Event Data | ||||
TalkMed Group Ltd Frequently Asked Questions
What is TalkMed Group Ltd(SGX:5G3)'s stock price today?
The current price of SGX:5G3 is S$0.45. The 52 week high of SGX:5G3 is S$0.50 and 52 week low is S$0.36.
When is next earnings date of TalkMed Group Ltd(SGX:5G3)?
The next earnings date of TalkMed Group Ltd(SGX:5G3) is .
Does TalkMed Group Ltd(SGX:5G3) pay dividends? If so, how much?
The Dividend Yield %  of TalkMed Group Ltd(SGX:5G3) is 4.89% (As of Today), Highest Dividend Payout Ratio of TalkMed Group Ltd(SGX:5G3) was 1.21. The lowest was 0.53. And the median was 0.89. The  Forward Dividend Yield % of TalkMed Group Ltd(SGX:5G3) is 4.89%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers